MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
Nacho Aguilo, Santiago Uranga, Dessislava Marinova, Marta Monzon, Juan Badiola, Carlos Martin, Nacho Aguilo, Santiago Uranga, Dessislava Marinova, Marta Monzon, Juan Badiola, Carlos Martin
Abstract
Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG.
Keywords: MTBVAC; Neonates; Newborn mice; Tuberculosis vaccine.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4727503/bin/gr1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4727503/bin/gr2.jpg)
Figure 3
Protective efficacy conferred by vaccination…
Figure 3
Protective efficacy conferred by vaccination at birth in C57/BL6 mice. Groups of three…
- Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis.Clark S, Lanni F, Marinova D, Rayner E, Martin C, Williams A. Clark S, et al. J Infect Dis. 2017 Sep 1;216(5):525-533. doi: 10.1093/infdis/jix030. J Infect Dis. 2017. PMID: 28329234
- Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice.Solans L, Uranga S, Aguilo N, Arnal C, Gomez AB, Monzon M, Badiola JJ, Gicquel B, Martin C. Solans L, et al. Vaccine. 2014 Sep 8;32(40):5192-7. doi: 10.1016/j.vaccine.2014.07.047. Epub 2014 Jul 25. Vaccine. 2014. PMID: 25066740
- Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S, Geldenhuys H, Shenje J, Luabeya AKK, Murillo I, Doce J, Aguilo N, Marinova D, Puentes E, Rodríguez E, Gonzalo-Asensio J, Fritzell B, Thole J, Martin C, Scriba TJ, Hatherill M; MTBVAC Clinical Trial Team. Tameris M, et al. Lancet Respir Med. 2019 Sep;7(9):757-770. doi: 10.1016/S2213-2600(19)30251-6. Epub 2019 Aug 12. Lancet Respir Med. 2019. PMID: 31416768 Clinical Trial.
- A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.Zelmer A, Tanner R, Stylianou E, Damelang T, Morris S, Izzo A, Williams A, Sharpe S, Pepponi I, Walker B, Hokey DA, McShane H, Brennan M, Fletcher H. Zelmer A, et al. BMC Infect Dis. 2016 Aug 12;16:412. doi: 10.1186/s12879-016-1751-4. BMC Infect Dis. 2016. PMID: 27519524 Free PMC article.
- [Novel vaccines against M. tuberculosis].Okada M. Okada M. Kekkaku. 2006 Dec;81(12):745-51. Kekkaku. 2006. PMID: 17240920 Review. Japanese.
- Fighting Tuberculosis: In Search of a BCG Replacement.Nadolinskaia NI, Kotliarova MS, Goncharenko AV. Nadolinskaia NI, et al. Microorganisms. 2022 Dec 23;11(1):51. doi: 10.3390/microorganisms11010051. Microorganisms. 2022. PMID: 36677343 Free PMC article. Review.
- The Rv3874-Rv3875 chimeric protein shows a promiscuous serodiagnostic potential for tuberculosis.Mahmood N, Akhter M, Hussain N, Shad M, Nisa ZU, Khan IH, Akhtar MW. Mahmood N, et al. Tuberculosis (Edinb). 2022 Sep;136:102253. doi: 10.1016/j.tube.2022.102253. Epub 2022 Aug 30. Tuberculosis (Edinb). 2022. PMID: 36067572 Free PMC article.
- Recombinant BCG Expressing the Subunit 1 of Pertussis Toxin Induces Innate Immune Memory and Confers Protection against Non-Related Pathogens.Kanno AI, Boraschi D, Leite LCC, Rodriguez D. Kanno AI, et al. Vaccines (Basel). 2022 Feb 3;10(2):234. doi: 10.3390/vaccines10020234. Vaccines (Basel). 2022. PMID: 35214691 Free PMC article.
- A review of the BCG vaccine and other approaches toward tuberculosis eradication.Cho T, Khatchadourian C, Nguyen H, Dara Y, Jung S, Venketaraman V. Cho T, et al. Hum Vaccin Immunother. 2021 Aug 3;17(8):2454-2470. doi: 10.1080/21645515.2021.1885280. Epub 2021 Mar 26. Hum Vaccin Immunother. 2021. PMID: 33769193 Free PMC article. Review.
- BCG-induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for next-generation vaccines.Foster M, Hill PC, Setiabudiawan TP, Koeken VACM, Alisjahbana B, van Crevel R. Foster M, et al. Immunol Rev. 2021 May;301(1):122-144. doi: 10.1111/imr.12965. Epub 2021 Mar 12. Immunol Rev. 2021. PMID: 33709421 Free PMC article. Review.
-
- Marinova D., Gonzalo-Asensio J., Aguilo N., Martin C. Recent developments in tuberculosis vaccines. Expert Rev Vaccines. 2013;12(12):1431–1448. - PubMed
-
- Mangtani P., Abubakar I., Ariti C., Beynon R., Pimpin L., Fine P.E., Rodrigues L.C., Smith P.G., Lipman M., Whiting P.F., Sterne J.A. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–480. - PubMed
-
- Pym A.S., Brodin P., Brosch R., Huerre M., Cole S.T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol. 2002;46(3):709–717. - PubMed
-
- Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., Dos Santos S., Duthoy S., Lacroix C., Garcia-Pelayo C., Inwald J.K., Golby P., Garcia J.N., Hewinson R.G., Behr M.A., Quail M.A., Churcher C., Barrell B.G., Parkhill J., Cole S.T. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A. 2007;104(13):5596–5601. - PMC - PubMed
- Comparative Study
- Research Support, Non-U.S. Gov't
- Animals
- Animals, Newborn
- BCG Vaccine / immunology
- BCG Vaccine / pharmacology
- Disease Models, Animal
- Interferon-gamma / immunology
- Interferon-gamma / metabolism
- Mice, Inbred C57BL
- Mycobacterium tuberculosis / growth & development*
- Spleen / drug effects
- Spleen / immunology
- Spleen / metabolism
- Time Factors
- Tuberculosis / immunology
- Tuberculosis / microbiology
- Tuberculosis / prevention & control*
- Tuberculosis Vaccines / immunology
- Tuberculosis Vaccines / pharmacology*
- Tuberculosis Vaccines / toxicity
- Weight Gain
- BCG Vaccine
- MTBVAC vaccine
- Tuberculosis Vaccines
- Interferon-gamma
- Full Text Sources
- Other Literature Sources
- Medical
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4727503/bin/gr3.jpg)
References
- Marinova D., Gonzalo-Asensio J., Aguilo N., Martin C. Recent developments in tuberculosis vaccines. Expert Rev Vaccines. 2013;12(12):1431–1448.
- Mangtani P., Abubakar I., Ariti C., Beynon R., Pimpin L., Fine P.E., Rodrigues L.C., Smith P.G., Lipman M., Whiting P.F., Sterne J.A. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–480.
- Pym A.S., Brodin P., Brosch R., Huerre M., Cole S.T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol. 2002;46(3):709–717.
- Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., Dos Santos S., Duthoy S., Lacroix C., Garcia-Pelayo C., Inwald J.K., Golby P., Garcia J.N., Hewinson R.G., Behr M.A., Quail M.A., Churcher C., Barrell B.G., Parkhill J., Cole S.T. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A. 2007;104(13):5596–5601.
- Copin R., Coscolla M., Efstathiadis E., Gagneux S., Ernst J.D. Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette–Guerin (BCG) Vaccine. 2014;32(45):5998–6004.
- Brites D., Gagneux S. Co-evolution of Mycobacterium tuberculosis and homo sapiens. Immunol Rev. 2015;264(1):6–24.
- Arbues A., Aguilo J.I., Gonzalo-Asensio J., Marinova D., Uranga S., Puentes E., Fernandez C., Parra A., Cardona P.J., Vilaplana C., Ausina V., Williams A., Clark S., Malaga W., Guilhot C., Gicquel B., Martin C. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 2013;31(42):4867–4873.
- Gonzalo-Asensio J., Mostowy S., Harders-Westerveen J., Huygen K., Hernandez-Pando R., Thole J., Behr M., Gicquel B., Martin C. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS One. 2008;3(10):e3496.
- Camacho L.R., Ensergueix D., Perez E., Gicquel B., Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol. 1999;34(2):257–267.
- Spertini F., Audran R., Chakour R., Karoui O., Steiner-Monard V., Thierry A.-C., Mayor C.E., Rettby N., Jaton K., Vallotton L., Lazor C., Doce J., Puentes E., Marinova D., Aguilo N., Martin C. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med. 2015;3(12):953–962.
- Guerrero G.G., Debrie A.S., Locht C. Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis. Vaccine. 2010;28(27):4340–4347.
- Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., Shea J.E., McClain J.B., Hussey G.D., Hanekom W.A., Mahomed H., McShane H. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–1028.
- Beverley P. TB vaccine failure was predictable. Nature. 2013;503(7477):469.
- Kashangura R., Sena E.S., Young T., Garner P. Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. Int J Epidemiol. 2015 Sep 8 pii: dyv142.
- Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., Soto C.Y., Clark S.O., Hatch G.J., Aguilar D., Ausina V., Gicquel B. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine. 2006;24(17):3408–3419.
- Solans L., Uranga S., Aguilo N., Arnal C., Gomez A.B., Monzon M., Badiola J.J., Gicquel B., Martin C. Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice. Vaccine. 2014;32(40):5192–5197.
- Horwitz M.A., Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun. 2003;71(4):1672–1679.
Source: PubMed